Healthcare Industry News: HSMN NewsFeed
News Release - February 13, 2019
Bausch & Lomb Receives 510(k) Clearance For Use Of The Tangible(R) Hydra-PEG(R) Custom Contact Lens Coating Technology On Several Of Its Boston(R) Gas Permeable Lens Materials And Zenlens(TM) Family Of Scleral LensesCoating Technology offers Improved Lens Wettability for Patients with Challenging Vision Needs
BRIDGEWATER, N.J., Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced it has received 510(k) clearance for use of the Tangible® Hydra-PEG® custom contact lens coating technology with some of its leading Boston® gas permeable (GP) materials, the Boston XO®, Boston XO2®, Boston EO® and Boston ES® lenses, including those utilized in the Zenlens™ scleral lens family. Designed to address contact lens discomfort and dryness, the Tangible® Hydra-PEG® is a high-water polymer coating that is bonded to the surface of a contact lens. With this coating technology, eye care professionals have the opportunity to enhance contact lens customization for their patients using these Bausch & Lomb lens offerings.
"The approval of the Hydra-PEG coating technology allows eye care professionals to offer improved lens wettability when using some of our key Boston® GP materials or Zenlens™ scleral lenses, which demonstrates our ongoing commitment to bringing advancements that help meet the challenging vision needs of this patient segment," said Joe Gordon, U.S. President, Bausch & Lomb. "We continue to provide eye care professionals innovative specialty contact lens materials and support through our Boston® brand of products, which have been available for decades."
In June 2018, Bausch & Lomb entered into a worldwide licensing agreement with Tangible Science, LLC, a company whose mission is to create technologies that improve the contact lens wearing experience, to offer the Tangible Science Hydra-PEG® advanced contact lens coating technology on specific materials and lenses from its specialty contact lens business.
"Specialty contact lenses and the ability to offer customizable solutions are important for patients with challenging visual needs," said Maria K. Walker, O.D., FAAO, FSLS, visiting professor, University of Houston College of Optometry, Houston. "The availability of the Tangible® Hydra-PEG® coating with Bausch & Lomb Specialty Vision Products will enable practitioners to offer patients additional solutions for their demanding visual requirements."
For more information on the Bausch & Lomb Specialty Vision Products portfolio, visit www.bauschsvp.com.
About Bausch & Lomb
Bausch & Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch & Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Bausch & Lomb, Boston, Boston XO, Boston XO2, Boston EO, Boston ES, Zenlens and Zen RC are trademarks of Bausch & Lomb Incorporated or its affiliates. Tangible Science, Tangible and Hydra-PEG are trademarks of Tangible Science, LLC.
© 2019 Bausch & Lomb Incorporated
Source: Bausch Health Companies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch & Lomb ULTRA(R) Multifocal for Astigmatism Contact Lenses Now Available in the United States
Bausch & Lomb Announces the U.S. Launch of LOTEMAX(R) SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the Treatment of Postoperative Inflammation and Pain Following Ocular Surgery